The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Companion Diagnostic Tests in Oncology-Global Market Insights and Sales Trends 2024
Synopsis
Increasing incidence of cancer, rising cost burden of cancer treatment, and increasing mortalities due to cancer, are some of the major reasons for increasing demand for new and technologically advanced treatment options, therapies, and drugs for the treatment of cancer.
The global Companion Diagnostic Tests in Oncology market size is expected to reach US$ 7598.1 million by 2029, growing at a CAGR of 9.5% from 2023 to 2029. The market is mainly driven by the significant applications of Companion Diagnostic Tests in Oncology in various end use industries. The expanding demands from the Pharmaceutical & Biotechnology Companies, Medical Device Companies, Research Institutes and Others, are propelling Companion Diagnostic Tests in Oncology market. Protein Detection, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the DNA Detection segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Companion Diagnostic Tests in Oncology, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Companion Diagnostic Tests in Oncology market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Companion Diagnostic Tests in Oncology market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Companion Diagnostic Tests in Oncology sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Companion Diagnostic Tests in Oncology covered in this report include Abbott, Roche, Genomic Health, QIAGEN, Agilent, Agendia, BioMerieux, Illumina and Siemens Healthcare, etc.
The global Companion Diagnostic Tests in Oncology market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbott
Roche
Genomic Health
QIAGEN
Agilent
Agendia
BioMerieux
Illumina
Siemens Healthcare
Thermo Fisher
Global Companion Diagnostic Tests in Oncology market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Companion Diagnostic Tests in Oncology market, Segment by Type:
Protein Detection
DNA Detection
Global Companion Diagnostic Tests in Oncology market, by Application
Pharmaceutical & Biotechnology Companies
Medical Device Companies
Research Institutes
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Companion Diagnostic Tests in Oncology companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Increasing incidence of cancer, rising cost burden of cancer treatment, and increasing mortalities due to cancer, are some of the major reasons for increasing demand for new and technologically advanced treatment options, therapies, and drugs for the treatment of cancer.
The global Companion Diagnostic Tests in Oncology market size is expected to reach US$ 7598.1 million by 2029, growing at a CAGR of 9.5% from 2023 to 2029. The market is mainly driven by the significant applications of Companion Diagnostic Tests in Oncology in various end use industries. The expanding demands from the Pharmaceutical & Biotechnology Companies, Medical Device Companies, Research Institutes and Others, are propelling Companion Diagnostic Tests in Oncology market. Protein Detection, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the DNA Detection segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Companion Diagnostic Tests in Oncology, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Companion Diagnostic Tests in Oncology market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Companion Diagnostic Tests in Oncology market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Companion Diagnostic Tests in Oncology sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Companion Diagnostic Tests in Oncology covered in this report include Abbott, Roche, Genomic Health, QIAGEN, Agilent, Agendia, BioMerieux, Illumina and Siemens Healthcare, etc.
The global Companion Diagnostic Tests in Oncology market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbott
Roche
Genomic Health
QIAGEN
Agilent
Agendia
BioMerieux
Illumina
Siemens Healthcare
Thermo Fisher
Global Companion Diagnostic Tests in Oncology market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Companion Diagnostic Tests in Oncology market, Segment by Type:
Protein Detection
DNA Detection
Global Companion Diagnostic Tests in Oncology market, by Application
Pharmaceutical & Biotechnology Companies
Medical Device Companies
Research Institutes
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Companion Diagnostic Tests in Oncology companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Companion Diagnostic Tests in Oncology
1.1 Companion Diagnostic Tests in Oncology Market Overview
1.1.1 Companion Diagnostic Tests in Oncology Product Scope
1.1.2 Companion Diagnostic Tests in Oncology Market Status and Outlook
1.2 Global Companion Diagnostic Tests in Oncology Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Companion Diagnostic Tests in Oncology Market Size by Region (2018-2029)
1.4 Global Companion Diagnostic Tests in Oncology Historic Market Size by Region (2018-2023)
1.5 Global Companion Diagnostic Tests in Oncology Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Companion Diagnostic Tests in Oncology Market Size (2018-2029)
1.6.1 North America Companion Diagnostic Tests in Oncology Market Size (2018-2029)
1.6.2 Europe Companion Diagnostic Tests in Oncology Market Size (2018-2029)
1.6.3 Asia-Pacific Companion Diagnostic Tests in Oncology Market Size (2018-2029)
1.6.4 Latin America Companion Diagnostic Tests in Oncology Market Size (2018-2029)
1.6.5 Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (2018-2029)
2 Companion Diagnostic Tests in Oncology Market by Type
2.1 Introduction
2.1.1 Protein Detection
2.1.2 DNA Detection
2.2 Global Companion Diagnostic Tests in Oncology Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Companion Diagnostic Tests in Oncology Historic Market Size by Type (2018-2023)
2.2.2 Global Companion Diagnostic Tests in Oncology Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Companion Diagnostic Tests in Oncology Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Companion Diagnostic Tests in Oncology Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Companion Diagnostic Tests in Oncology Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Companion Diagnostic Tests in Oncology Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Companion Diagnostic Tests in Oncology Revenue Breakdown by Type (2018-2029)
3 Companion Diagnostic Tests in Oncology Market Overview by Application
3.1 Introduction
3.1.1 Pharmaceutical & Biotechnology Companies
3.1.2 Medical Device Companies
3.1.3 Research Institutes
3.1.4 Others
3.2 Global Companion Diagnostic Tests in Oncology Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Companion Diagnostic Tests in Oncology Historic Market Size by Application (2018-2023)
3.2.2 Global Companion Diagnostic Tests in Oncology Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Companion Diagnostic Tests in Oncology Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Companion Diagnostic Tests in Oncology Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Companion Diagnostic Tests in Oncology Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Companion Diagnostic Tests in Oncology Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Companion Diagnostic Tests in Oncology Revenue Breakdown by Application (2018-2029)
4 Companion Diagnostic Tests in Oncology Competition Analysis by Players
4.1 Global Companion Diagnostic Tests in Oncology Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Companion Diagnostic Tests in Oncology as of 2022)
4.3 Date of Key Players Enter into Companion Diagnostic Tests in Oncology Market
4.4 Global Top Players Companion Diagnostic Tests in Oncology Headquarters and Area Served
4.5 Key Players Companion Diagnostic Tests in Oncology Product Solution and Service
4.6 Competitive Status
4.6.1 Companion Diagnostic Tests in Oncology Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Abbott
5.1.1 Abbott Profile
5.1.2 Abbott Main Business
5.1.3 Abbott Companion Diagnostic Tests in Oncology Products, Services and Solutions
5.1.4 Abbott Companion Diagnostic Tests in Oncology Revenue (US$ Million) & (2018-2023)
5.1.5 Abbott Recent Developments
5.2 Roche
5.2.1 Roche Profile
5.2.2 Roche Main Business
5.2.3 Roche Companion Diagnostic Tests in Oncology Products, Services and Solutions
5.2.4 Roche Companion Diagnostic Tests in Oncology Revenue (US$ Million) & (2018-2023)
5.2.5 Roche Recent Developments
5.3 Genomic Health
5.3.1 Genomic Health Profile
5.3.2 Genomic Health Main Business
5.3.3 Genomic Health Companion Diagnostic Tests in Oncology Products, Services and Solutions
5.3.4 Genomic Health Companion Diagnostic Tests in Oncology Revenue (US$ Million) & (2018-2023)
5.3.5 QIAGEN Recent Developments
5.4 QIAGEN
5.4.1 QIAGEN Profile
5.4.2 QIAGEN Main Business
5.4.3 QIAGEN Companion Diagnostic Tests in Oncology Products, Services and Solutions
5.4.4 QIAGEN Companion Diagnostic Tests in Oncology Revenue (US$ Million) & (2018-2023)
5.4.5 QIAGEN Recent Developments
5.5 Agilent
5.5.1 Agilent Profile
5.5.2 Agilent Main Business
5.5.3 Agilent Companion Diagnostic Tests in Oncology Products, Services and Solutions
5.5.4 Agilent Companion Diagnostic Tests in Oncology Revenue (US$ Million) & (2018-2023)
5.5.5 Agilent Recent Developments
5.6 Agendia
5.6.1 Agendia Profile
5.6.2 Agendia Main Business
5.6.3 Agendia Companion Diagnostic Tests in Oncology Products, Services and Solutions
5.6.4 Agendia Companion Diagnostic Tests in Oncology Revenue (US$ Million) & (2018-2023)
5.6.5 Agendia Recent Developments
5.7 BioMerieux
5.7.1 BioMerieux Profile
5.7.2 BioMerieux Main Business
5.7.3 BioMerieux Companion Diagnostic Tests in Oncology Products, Services and Solutions
5.7.4 BioMerieux Companion Diagnostic Tests in Oncology Revenue (US$ Million) & (2018-2023)
5.7.5 BioMerieux Recent Developments
5.8 Illumina
5.8.1 Illumina Profile
5.8.2 Illumina Main Business
5.8.3 Illumina Companion Diagnostic Tests in Oncology Products, Services and Solutions
5.8.4 Illumina Companion Diagnostic Tests in Oncology Revenue (US$ Million) & (2018-2023)
5.8.5 Illumina Recent Developments
5.9 Siemens Healthcare
5.9.1 Siemens Healthcare Profile
5.9.2 Siemens Healthcare Main Business
5.9.3 Siemens Healthcare Companion Diagnostic Tests in Oncology Products, Services and Solutions
5.9.4 Siemens Healthcare Companion Diagnostic Tests in Oncology Revenue (US$ Million) & (2018-2023)
5.9.5 Siemens Healthcare Recent Developments
5.10 Thermo Fisher
5.10.1 Thermo Fisher Profile
5.10.2 Thermo Fisher Main Business
5.10.3 Thermo Fisher Companion Diagnostic Tests in Oncology Products, Services and Solutions
5.10.4 Thermo Fisher Companion Diagnostic Tests in Oncology Revenue (US$ Million) & (2018-2023)
5.10.5 Thermo Fisher Recent Developments
6 North America
6.1 North America Companion Diagnostic Tests in Oncology Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Companion Diagnostic Tests in Oncology Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Companion Diagnostic Tests in Oncology Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Companion Diagnostic Tests in Oncology Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Companion Diagnostic Tests in Oncology Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Companion Diagnostic Tests in Oncology Market Dynamics
11.1 Companion Diagnostic Tests in Oncology Industry Trends
11.2 Companion Diagnostic Tests in Oncology Market Drivers
11.3 Companion Diagnostic Tests in Oncology Market Challenges
11.4 Companion Diagnostic Tests in Oncology Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
